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 2 
Abstract 26 
 27 
Subcellular compartmentalisation is necessary for eukaryotic cell function. Spatial 28 
and temporal regulation of kinesin activity is essential for building these local 29 
environments via control of intracellular cargo distribution. Kinesin binding protein 30 
(KBP) interacts with a subset of kinesins via their motor domains, inhibits their 31 
microtubule (MT) attachment and blocks their cellular function. However, its 32 
mechanisms of inhibition and selectivity have been unclear. Here we use cryo-33 
electron microscopy to reveal the structure of KBP and of a KBP-kinesin motor 34 
domain complex. KBP is a TPR-containing, right-handed α-solenoid that sequesters 35 
the kinesin motor domain’s tubulin-binding surface, structurally distorting the motor 36 
domain and sterically blocking its MT attachment. KBP uses its α-solenoid concave 37 
face and edge loops to bind the kinesin motor domain, and selected structure-guided 38 
mutations disrupt KBP inhibition of kinesin transport in cells. The KBP-interacting 39 
motor domain surface contains motifs exclusively conserved in KBP-interacting 40 
kinesins, suggesting a basis for kinesin selectivity.  41 
 42 
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 3 
Introduction 44 
 45 
Kinesins are a superfamily of microtubule (MT)-based molecular motors that play 46 
important roles in cellular functions such as mitosis, cell motility and intracellular 47 
transport
1-3
. Kinesins are categorised into 14 sub-classes (kinesin-1 to kinesin-14
4
) by 48 
motor domain conservation and within these sub-classes individual family members 49 
(a total of 45 ‘KIF’ or ‘Kif’ genes in humans and mice respectively) have a wide 50 
range of functional characteristics and biological roles
1,5
. Dysfunction of kinesin 51 
family members has been implicated in a number of pathological conditions
6,7
. The 52 
kinesin motor domain is the microtubule-binding engine that drives these activities, 53 
converting the chemical energy of ATP binding and hydrolysis into mechanical force. 54 
While these mechanical forces are classically used to generate motility in transport 55 
kinesins, some kinesin family members drive MT organisation or depolymerisation of 56 
MTs. 57 
 Kinesins are highly regulated in order to prevent both waste of ATP and to 58 
spatially and temporally control kinesin function. This is particularly important in 59 
highly polarised and compartmentalised cells such as neurons. Kinesin regulation via 60 
inhibition of their motor domains can occur through a number of mechanisms that 61 
limit ATPase activity and/or block track binding - these include intramolecular 62 
inhibition by kinesin tail domains, post-translational modification of the motor, or 63 
through interactions with regulatory binding partners. Recently, it has been 64 
demonstrated that a subset of kinesin superfamily members, including kinesin-2s, -3s, 65 
-8s and -12s, are sequestered by kinesin binding protein (KBP; KIF1BP; KIAA1279), 66 
which inhibits MT track attachment by their motor domains and, thus, blocks their 67 
MT-related functions
8-10
.  68 
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 KBP is expressed in multiple human tissues including brain and heart
8
. 69 
Mutations in the KBP have been identified as causing autosomal recessive Goldberg-70 
Shprintzen syndrome (GOSHS)
11-14
, which presents as congenital facial dysmorphia, 71 
nervous system pathology and dysfunction and heart defects
15
. In addition, KBP gene 72 
copy number has been recently reported as predictive in paediatric neuroblastoma 73 
prognosis, prompting its suggestion as a drug target
16
. KBP was originally identified 74 
as a kinesin-3 binding partner that modulated its mitochondrial transport function
8
; 75 
however, KBP has since been shown to interact with a subset of other kinesin family 76 
members to regulate diverse cellular processes including mitosis
17,18
, 77 
spermatogenesis
19
 and neuronal differentiation, growth and cargo distribution
10,20-24
. 78 
 We do not currently know what the structure of KBP is, nor understand the 79 
mechanism of KBP-kinesin inhibition. It is also completely unknown how KBP 80 
differentiates between particular kinesin family members. KBP is a 72 kDa protein, is 81 
predicted to contain several tetratricopeptide repeats (TPRs) and to be mainly α-82 
helical in secondary structure content
8,9
. Here we present cryo-electron microscopy 83 
(cryo-EM) structures of KBP alone and of KBP bound to the motor domain of the 84 
human mitotic kinesin KIF15 (a 110 kDa complex). We show that KBP is a TPR-85 
containing, right-handed α-solenoid protein composed of 9 antiparallel α-helix pairs 86 
interrupted by a linker region. We also show that KBP’s concave face binds KIF15 87 
via its MT-binding elements and induces a large displacement of the kinesin α4 helix, 88 
sterically inhibiting MT association. Finally, we show that KBPs kinesin selectivity is 89 
associated with specific kinesin sequences spread across the interaction surface.  90 
  91 
 5 
Results 92 
 93 
KBP is a TPR-containing, right-handed α-solenoid 94 
 95 
The 3D structure of the ~72 kDa KBP at 4.6 Å resolution (Figure 1 and Figure 1–96 
figure supplement 1a,b) was determined using cryo-EM data collected using a Volta 97 
Phase Plate (VPP), and an atomic model was calculated (see Methods). Our structure 98 
revealed that KBP is a right-handed α-solenoid protein (Figure 1a,b and Figure 1–99 
figure supplement 1c-e). Nine pairs of anti-parallel α-helices (αHP1 (α-helical pair 1) 100 
to αHP9) are broken by a single ‘linker α-helix’ (LαH) and ‘linker loop’ (LL) in the 101 
centre of the fold separating KBP into N-terminal and C-terminal subdomains (Figure 102 
1 and Figure 1–figure supplement 1c-e, Figure 1–figure supplement 2). The four 103 
predicted TPR motifs contribute exclusively to α-helical pairs in the N-terminal 104 
subdomain (Figure 1a,d,e). 105 
 The supercoiling α-helical pairs form concave and convex faces linked by short 106 
and long loops that constitute the two edges of the α-solenoid (Figure 1–figure 107 
supplement 1c-e, Figure 1–figure supplement 2). In contrast to the shorter loops, the 108 
longer loops (>7 residues) tend to be partially disordered, show low sequence 109 
homology between KBP orthologues in different species and are mainly found in the 110 
N-terminal subdomain (e.g. L2, L6 and L10, Figure 1–figure supplement 1d-e, Figure 111 
1–figure supplement 2). The linker loop is the longest (62 residues) and is thus unique 112 
in the KBP structure because it is reasonably conserved and mainly ordered, with 113 
visible corresponding density clearly bridging the N and C-terminal subdomains 114 
(Figure 1a-b, Figure 1–figure supplement 1d-e, Figure 1–figure supplement 2 and 115 
Figure 1–figure supplement 3). Despite this clear ordered density, this loop was not 116 
 6 
modelled due to low homology to available structures and a lack of consensus in 117 
secondary structure prediction (see Methods). In spite of this lack of consensus, 118 
density in this region suggests that part of this loop may form further α-helical 119 
structures. Other TPR-containing α-solenoid proteins form important regulatory 120 
interactions in numerous contexts, and the structure we describe is indicative of 121 
similar properties for KBP. 122 
 123 
KBP conformationally adapts to bind KIF15’s motor domain using both 124 
subdomains 125 
 126 
To elucidate the mechanism of kinesin inhibition by KBP, we determined the 127 
structure of KBP in complex with the human KIF15 (kinesin-12) motor domain 128 
(KIF15_MD, 1-375). This construct, which has six of its eight cysteine residues 129 
mutated to serine (C5S, C50S, C162S, C294S, C314S, C346S) and two additional 130 
cysteines were inserted (S250C, G375C), has comparable steady state ATPase 131 
activity to previously published reports
25
 (Figure 2–figure supplement 1a) and we 132 
refer to it as KIF15_MD6S. The overall resolution of this KBP-KIF15_MD6S 133 
complex was 6.9 Å, with KBP and KIF15_MD6S determined to similar local 134 
resolutions (Figure 2–figure supplement 1b-c). We built a model of the complex via 135 
flexible fitting using our KBP model and the KIF15_MD crystal structure (Figure 136 
2a,b and see Methods). The complex is arranged such that KIF15_MD6S sits in the 137 
concave face of the KBP α-solenoid, analogous to a baseball enclosed in a baseball 138 
glove. The kinesin MD is positioned centrally between the N and C-terminal 139 
subdomains and contacts the KBP concave face and loops at the α-solenoid edges.  140 
 7 
 When the structure of KBP-alone is superimposed onto KBP in the KBP-141 
KIF15_MD6S complex, it is clear that KBP undergoes a conformational change in the 142 
presence of its kinesin motor domain binding partner, with the largest differences 143 
resulting from an unfurling motion of its N-terminal subdomain (Figure 2c,d and 144 
Video 1). The KBP-alone model is incompatible with KIF15_MD6S binding, due to 145 
clashes with L14 in the C-terminal subdomain and αHP3a, αHP4a and L8 in the N-146 
terminal subdomain. The conformational changes in KBP upon KIF15_MD6S 147 
binding relieves these clashes in the complex (Video 1).  148 
 To establish whether the KBP-KIF15_MD6S mode of interaction applied to 149 
other kinesins, we also collected data of the complex formed by KBP with the motor 150 
domain of the human kinesin-3 KIF1A (KIF1A_MD). 2D classification of these 151 
images revealed a number of classes with an extra-density corresponding the size of a 152 
kinesin motor domain bound to the concave face of KBP, consistent with what was 153 
observed in the KBP-KIF15_MD6S dataset (Figure 2–figure supplement 1c). 154 
However, in contrast to the KBP-KIF15_MD6S sample, these KBP-KIF1A_MD 2D 155 
classes provided only limited views of the complex (Figure 2–figure supplement 156 
1c,d), such that a reliable 3D structure could not be calculated. Intriguingly, in 157 
addition, the extra kinesin density in the 2D classes appeared to have a somewhat 158 
flexible position relative to KBP. However, these data did allow us to confirm that 159 
indeed KIF1A_MD also interacts with KBP on its concave face in the same way as 160 
KIF15_MD6S and suggests a common mechanism of kinesin inhibition by KBP. 161 
 162 
KIF15_MD6S binds KBP via rearrangement of its tubulin-binding subdomain 163 
 164 
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We examined the effect of KBP binding on the conformation of KIF15_MD6S. 165 
Kinesin motor domains can be structurally divided into three distinct subdomains
26,27
 166 
which undergo coordinated conformational changes during the MT-based kinesin 167 
ATPase cycle. MT binding stabilises the tubulin-binding subdomain of the MD while 168 
the P-loop and Switch 1/2 subdomains – which contain the conserved nucleotide-169 
coordinating P-loop and Switch 1 and 2 motifs - move relative to each other in 170 
response to the nucleotide state of the MD
26-28
. We determined the structure of the 171 
MT-bound, AMPPNP state of KIF15_MD6S, which shows that this MD adopts a 172 
canonical conformation (Figure 3–figure supplement 1). Comparison of this 173 
conformation with an ADP-bound Kif15_MD crystal structure (PDB: 4BN2
25
) 174 
illustrates the scale of these MT- and nucleotide-dependent subdomain 175 
rearrangements in KIF15, which are similar to those seen in other kinesins MDs
26,28,29
 176 
(Figure 3–figure supplement 1d,e and Figure 3c,d).  177 
 The structure of the KBP-KIF15_MD6S complex revealed that KBP binds the 178 
kinesin motor domain via the tubulin-binding subdomain (Figure 3). While the P-loop 179 
and Switch 1/2 subdomains of the KIF15_MD crystal structure and associated Mg
2+
-180 
ADP generally fitted well into density of the KBP-KIF15_MD6S complex, a large 181 
portion of the tubulin-binding subdomain did not (Figure 3a; Figure 3–figure 182 
supplement 2a,b). In particular, there is a striking lack of density in the expected 183 
position for helix α4 (Figure 3a; Figure 3–figure supplement 2b). Instead, there was 184 
strong density of length and width consistent with helix α4 displaced by ~15 Å into 185 
the concave face of KBP, and which we modelled as such (Figure 3b,e, Figure 2 and 186 
Figure 3–figure supplement 2b-e). This displacement of helix α4, which lies close to 187 
the TPR-repeat region of the N-terminal subdomain of KBP, is accompanied by 188 
additional rearrangements of the flanking L11 and L12 in KIF15_MD6S (labelled 189 
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KL11 and KL12, Figure 3c-e: Figure 3–figure supplement 2b-e). A number of other 190 
TPR-containing α-solenoids are known to bind peptide motifs with α-helical content 191 
within their concave faces
30-32
 (Figure 3–figure supplement 3), and our structure 192 
shows that KBP binds helix α4 of KIF15_MD6S in a similar way.  193 
 The KBP-bound conformation of the KIF15_MD6S tubulin-binding subdomain 194 
is also radically different from its MT-bound conformation (Figure 3d-e). The 195 
tubulin-binding subdomain forms the majority of the MT-binding surface in the 196 
KIF15_MD6S-MT complex (Figure 3d, Figure 3–figure supplement 1) such that KBP 197 
and MTs cannot simultaneously bind KIF15_MD6S due to extensive steric overlap 198 
(Figure 3d-e). In summary, KBP sequesters and blocks the MT-interacting surface of 199 
kinesin motor domains via a mechanism that involves significant conformational 200 
change within the motor domain. 201 
 202 
KBP binds kinesin motor domains via conserved motifs in the α-solenoid edge loops 203 
and α-helices at the concave face  204 
 205 
KBP contacts the KIF15_MD6S both via 1) loops connecting the α-solenoid edges 206 
and 2) TPR-containing α-helices at the concave face (Figure 4, Figure 4–figure 207 
supplement 1 and Video 2). At the α-solenoid edges, L1, L3, L5 and L10 in the N-208 
terminal subdomain and L12, L14, L16 and L18 in the C-terminal subdomain are 209 
close enough to KIF15_MD6S to be involved in binding. The closest interaction of 210 
these were KBP L12 and L14, which contact both Kβ5-KL8 and KL12-Kα5-KL13 211 
regions of the KIF15 tubulin-binding subdomain (Figure 4). KBP’s disordered L1 lies 212 
close to KIF15_MD6S’s KL9, while the shorter, ordered L3 and L5 are situated near 213 
but not contacting KL11 and Kα6 (Figure 4–figure supplement 1a,b). KBP’s C-214 
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terminal L16 and L18 are close enough to KIF15_MD6S that they may interact with 215 
the flexible KL12, N-terminus or neck-linker. At the TPR-containing region of the 216 
concave face of KBP, αHP4a, αHP4b and αHP5a contact the K11-Kα4-KL12 region 217 
of KIF15_MD6S (Figure 4c-d). 218 
 To test the functional significance of this interface, we investigated KBP-219 
kinesin interactions in cells, and examined the activities of mutant KBP constructs in 220 
which the predicted interacting amino acids within potentially kinesin-contacting 221 
loops were substituted for Ala, Gly or Pro residues (Figure 1–figure supplement 2, 222 
and Table 2). Ala-substitutions in the TPR-containing α-helices at the KBP concave 223 
face were also introduced at particularly inter-species conserved polar residues 224 
predicted to interact with the KIF15_MD K11-Kα4-KL12 region (Tyr-213 and Gln-225 
216 in αHP4a, Gln-238 in αHP4b, Thr-255 and Gln-258 in αHP5a; Figure 4c,d and 226 
Figure 1–figure supplement 2). All mutant constructs exhibited roughly equivalent 227 
expression patterns which were also comparable to WT KBP (Figure 5 – figure 228 
supplement 1). 229 
 We first used pull-down assays. Mouse Kif15 or Kif1A constructs consisting of 230 
only the motor domain and the first coiled-coil region (Kif15_MDC or Kif1A_MDC) 231 
were fused to bioGFP and co-expressed with various HA-tagged human KBP 232 
constructs in HEK293T cells, followed by pull-down of HA-KBP by the bioGFP-233 
KIF_MDC
9
 (Figure 5–figure supplement 2). Although there are moderate qualitative 234 
differences in binding by the two motors, the effects of KBP mutations on motor 235 
binding – described in following - are essentially the same. Ala-substitutions in the 236 
TPR-containing α-helices at the KBP concave face (αHP4a, αHP4b), which lie at the 237 
heart of the KBP- KIF15_MD6S structural interface, strongly reduced KBP’s 238 
interaction with both KIF15_MDC and KIF1A_MDC. αHP5a mutants had a similar 239 
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but less pronounced effect (Figure 5–figure supplement 2b,c). In contrast, mutation of 240 
L1, L3 or L5 in the KBP N-terminal subdomain or L10 or L16 in the C-terminal 241 
subdomain – none of which form directly visualised interactions with KIF15_MD6S 242 
in the cryo-EM reconstruction - has no effect on KBP’s interaction with either 243 
KIF15_MDC or KIF1A_MDC (Figure 5–figure supplement 2b,c). Mutation of L12 244 
(to some extent) and of L14 (to a greater extent) – which contact both Kβ5-KL8 and 245 
KL12-Kα5-KL13 - reduced KBP interaction with KIF15_MDC and KIF1A_MDC 246 
(Figure 5–figure supplement 2 b,c). Mutation of L12 + L14 additively disrupted the 247 
KBP-motor interaction, consistent with the structural proximity of these two loops in 248 
the kinesin-KBP complex. L10 + L12 and L10 + L14 mutants also had weaker 249 
interactions with KIF15_MDC/KIF1A_MDC (Figure 5–figure supplement 2 b,c), 250 
again pointing to the additive contributions of loops in the KBP C-terminal 251 
subdomain to kinesin binding. Strikingly, mutation of L18 appears to enhance the 252 
interaction between KBP and both KIF15_MDC and KIF1A_MDC, suggesting that it 253 
may somehow contribute to negative regulation of binding in the context of WT KBP. 254 
 We then used a previously described inducible peroxisome translocation assay 255 
in COS-7 cells
9
. In this assay, dimeric mouse Kif15_MDC or Kif1A_MDC constructs 256 
with an FRB-tag (Kif15_MDC-FRB or Kif1A_MDC-FRB) are expressed together 257 
with PEX-mRFP-FKBP, a peroxisome-binding construct, along with the various KBP 258 
constructs. Addition of rapalog induces FRB-FKBP heterodimerisation and motor-259 
driven peroxisome translocation to the cell periphery, but when the motor is inhibited 260 
by KBP, peroxisome translocation is blocked (Figure 5a-c). Kinesin-mediated 261 
translocation was measured, first by quantifying the number of cells in which 262 
peroxisome translocation is seen (Figure 5 d, e), and second, by quantifying 263 
peroxisome intensities above a threshold value in the cell periphery (Figure 5 f, g). 264 
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Because of observed differences in peroxisome translocation within the time-frame of 265 
rapalog treatment, different peroxisome intensity threshold values and peripheral 266 
areas were used for KIF1A and KIF15; this is probably due to differences in motor 267 
properties (Figure 5 – figure supplement 3).  268 
 Intriguingly, while the overall trends in perturbation of KBP inhibition by 269 
mutagenesis seen in the pulldown assay are recapitulated in the translocation assay, 270 
some differences are also observed. As with the pull-down assay, Ala-substitutions in 271 
the TPR-containing α-helices αHP4a and αHP4b at the KBP concave face, as well as 272 
αHP5a, all strongly reduced KBP’s inhibition of both KIF15_MDC and KIF1A_MDC 273 
peroxisome translocation activity (Figure 5d-g). This can be seen by the extent of 274 
peroxisome translocation and in an increase of peroxisomes in the cell periphery after 275 
rapalog addition, similar to the control condition without KBP (Figure 5d-g). Also, as 276 
observed in the pull-down assay, mutation of L1, L3 or L5 had no effect on KBP’s 277 
inhibition of KIF15_MDC or KIF1A_MDC (Figure 5d-g). This reinforces the 278 
conclusion that while these elements are close enough to form contacts with the parts 279 
of the kinesin motor domain in our reconstruction, they do not contribute significantly 280 
to KBP inhibition of kinesin-mediated translocation in cells. 281 
 Mutation of either of L12 or L14 strongly abrogated KBP inhibition of 282 
KIF15_MDC/KIF1A_MDC-based translocation, a more pronounced effect than was 283 
seen in the pull-down assay. Similarly, although mutation of L10 and L16 had no 284 
effect on KBP-kinesin interaction in the pull-down assay, mutation of these loops 285 
disrupted KBP inhibition of KIF1A_MDC and KIF15_MDC in the translocation 286 
assay (Figure 5d-g). A subset of the above described mutations were also combined to 287 
assess additive effects. Here we observed that KBP constructs containing mutations in 288 
both L10 + L12, L10 + L14 or L12 + L14 had similar effects to KBP with only one of 289 
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the loops mutated (Figure 5d-g), suggesting that KBP inhibition is more readily 290 
disrupted in the translocation assay.   291 
 Interestingly, while all the above described regions affected KBP inhibition of 292 
KIF15_MDC and KIF1A_MDC equivalently, the L18 KBP mutant inhibited 293 
KIF15_MDC equivalent to wild type, but only exhibited partial inhibition of 294 
KIF1A_MDC-mediated translocation. It should, however, be noted that fewer cells 295 
show peroxisome translocation by KIF1A_MDC when L18 is co-expressed (Figure 296 
5e), suggesting that the L18 KBP mutant also inhibits KIF1A_MDC to some extent. 297 
The L18 mutant is the single example of contradictory behaviours between the assays, 298 
because it appeared to enhance KBP-kinesin binding in the pull-down assay. Our 299 
structural data do not provide a clear rationale for this, and future studies will 300 
investigate the role of this region of KBP further and, for example, whether it is 301 
subject to post-translational regulation that could regulate KBP’s inhibitory activity. 302 
 However, taken together, the translocation and pull-down assays both 303 
demonstrate the functional importance of the kinesin interaction with the TPR-304 
containing α-helices at the KBP concave face and the set of loops in the KBP C-305 
terminal subdomain. The translocation and pull-down assays also reveal differences in 306 
the sensitivity of the KBP-kinesin interaction to perturbation, where translocation is 307 
more readily disrupted than the interactions detected by pull-down. These differences 308 
likely reflect the greater complexity of motor regulation during active translocation 309 
and could be a function of FRB-FKBP-mediated motor dimerization. It might also 310 
reflect the fact that cellular MTs in the translocation assay can directly compete with 311 
KBP for kinesin binding. Overall, these mutation studies support the idea that KBP 312 
interacts with different kinesin family members in a similar way via an extended 313 
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interface at KBP’s concave face that is composed of TPR-containing α-helices and α-314 
solenoid edge loops, particularly in the C-terminal subdomain. 315 
 316 
Specific sequences in the tubulin-binding subdomain are conserved across KBP-317 
binding kinesin family members 318 
 319 
Given that KBP selectively binds and inhibits only a subset of kinesins
9
, we used our 320 
structural data to investigate the basis of this selectivity. Although the resolution of 321 
our reconstruction and the flexibility of some loops do not provide a detailed 322 
molecular description of the interaction interface, our structure shows that the kinesin 323 
tubulin-binding subdomain is the key KBP-interacting region. Analysis of the 324 
sequences of this region in KBP-binding and KBP-non-binding kinesins (Figure 6a) 325 
revealed patterns of sequence conservation across the entire subdomain in all KBP-326 
binding kinesins; this included both the Kβ5-KL8 and KL11-Kα4-KL12-Kα5-KL13 327 
regions. In contrast, the equivalent regions are more variable in kinesins that are not 328 
inhibited by KBP. The length of KL8, which joins the two Kβ5 strands, was also 329 
consistently 5 residues long in KBP-binding kinesins, while it was variable in KBP-330 
non-binding kinesins. From our KBP- KIF15_MD6S structure, the sensitivity of the 331 
KBP interaction to KL8 length makes sense considering the tight fit of this loop 332 
between KBP L12 and L14 (Figure 6b). In summary, two consensus motifs in KL11-333 
Kα4-KL12-Kα5-KL13 and Kβ5-KL8 regions of the tubulin-binding subdomain are 334 
found in KBP-binding kinesins and these are likely to form the basis of KBP’s kinesin 335 
family member selectivity. We therefore propose a model where KBP selects and 336 
inhibits target kinesins through binding and remodelling a compatible tubulin-binding 337 
subdomain, obstructing the kinesin MT-binding surface (Figure 6c). 338 
 15 
 339 
Discussion 340 
 341 
In this study, we reveal the TPR-containing right-handed α-solenoid structure of the 342 
~72 kDa KBP using VPP cryo-EM. At the time of writing and to our knowledge, 343 
structures of only a few macromolecular complexes <80 kDa have been determined 344 
using cryo-EM
33-37
. The structure of the KBP-KIF15_MD6S complex shows how 345 
KBP binds the KIF15_MD6S via its concave face and undergoes subtle remodelling 346 
of its N-terminal domain to accommodate kinesin binding. This further reinforces the 347 
idea that the TPR-containing structures are not simply static scaffolds but can flexibly 348 
respond to ligand binding
38
. In contrast, the KIF15 motor domain undergoes a radical 349 
conformational change in forming a complex with KBP, in which helix α4, the major 350 
component of the motor’s tubulin-binding subdomain, is displaced from the main MD 351 
body by ~15 Å into the KBP concave face. This is consistent with previous 352 
observations that this region of the kinesin motor domain being rather malleable and 353 
able to move independently of the core structure of kinesin motor domains
39,40
. Our 354 
evidence suggests this observation is not due to use of a cysteine-substituted KIF15 355 
motor domain construct because: i) this protein exhibited equivalent MT-stimulated 356 
ATPase activity compared to non-substituted KIF15_MD (Figure 2 – figure 357 
supplement 2a), ii) it exhibited structurally canonical MT binding and response to 358 
nucleotide (Figure 3 – figure supplement 1), and iii) the substituted residues are not 359 
well conserved among KBP-binding kinesins (Figure 6a). The large displacement of 360 
helix α4 expands the surface area over which the normally compact tubulin-binding 361 
subdomain of the kinesin motor domain can interact with KBP, and it is through the 362 
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sequence and shape of this interface that the selectivity of KBP for a subset of kinesin 363 
motors is presumably defined.  364 
 Analysis of the KBP-KIF1A_MD complex (Figure 2–figure supplement 1c) 365 
supports the idea of a conserved mode of interaction between a subset of kinesins and 366 
the concave face of KBP. Interestingly, KIF1A_MD exhibited flexibility in its 367 
interaction with KBP, which was not observed in the KBP-KIF15_MD6S complex. 368 
Whether this reflects a physiological reality, or a result of the EM preparation method 369 
is uncertain at present, although we think it unlikely to be due to our use of 370 
KIF15_MD6S. However, our 2D classifications combined with mutation studies 371 
strongly suggest KIF15_MD6S and KIF1A_MD share an overall similar KBP binding 372 
mode.  373 
 Targeted mutations to the various kinesin-binding KBP elements reduced 374 
complex affinity, yet no single mutation completely disrupted the interaction in our 375 
pull-down assays (Figure 5- figure supplement 2). In contrast, in the context of active 376 
MT-based cargo translocation in the cellular environment, KBP inhibitory activity 377 
appeared more sensitive to disruption (Figure 5 d-g). Although most KBP mutations 378 
that have been reported in GOSHS result in total loss of protein
11-14
, a recent study 379 
details missense mutations that only partially reduce protein expression (MacKenzie 380 
et al, 2020). Our data illustrate that KBP’s activity is additionally sensitive to 381 
mutations in key regions that affect its ability to bind kinesins.  382 
 Our structure shows that KBP binds exclusively to the tubulin-binding 383 
subdomain of KIF15_MD6S, sterically preventing MT attachment. The interaction of 384 
kinesin motor domains with the MT surface via its tubulin-binding subdomain 385 
stimulates nucleotide exchange and kinesin ATPase activity. In contrast, on 386 
interaction with KBP, the displacement of helix α4 from the kinesin nucleotide-387 
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binding site, together with the absence of MT-mediated ordering of KL9 and KL11, 388 
means that its catalytic site is distorted and the structural changes associated with MT-389 
stimulated ATPase cannot occur. This could be an important facet of the role of KBP 390 
in the energy economy of the cell in addition to directly blocking kinesin-MT 391 
interactions.  392 
 The concave face of TPR-containing α-solenoids commonly serve as a 393 
recognition platform for specific peptide motifs, including those forming α-helical 394 
structures
41
. Specificity and affinity for target motifs are determined in part by the 395 
shape of the α-solenoid concave face, which in turn is defined by the fold’s 396 
supertwist. In addition, particular amino-acid arrangements at the concave face 397 
contribute to partner binding affinity and specificity, together with additional 398 
interfaces formed at the convex surface or α-solenoid edge
42
. KBP kinesin specificity 399 
and affinity is defined by the interaction of its concave face with the large surface area 400 
of the kinesin L11-Kα4-KL12-Kα5-KL13 region, in addition to binding the kinesin 401 
Kβ5-KL8 region at its α-solenoid edge. Interestingly, distal to the N-terminal MT-402 
binding region of kinesin-1, C-terminally-associated kinesin light chain use their 403 
unique TPR-containing α-solenoid concave face to select cargos via recognition of 404 
specific peptide motifs
43
. Therefore, peptide selectivity by TPR-containing α-405 
solenoids is a facet of both kinesin MT-binding and cargo-binding regulatory 406 
mechanisms. Such protein-protein interactions may be selectively targeted for 407 
disruption
44
, and the insights arising from our work provide future avenues to disrupt 408 
KBP-kinesin interactions and thereby explore KBP interactions and regulatory roles.  409 
 The effective and selective kinesin inhibitory mechanism of KBP revealed by 410 
our work may fulfil specific roles in the kinesin regulatory toolbox employed by cells 411 
to spatially and temporarily orchestrate kinesin activity. Future studies will be aimed 412 
 18 
at understanding how KBP interacts with kinesins in dimeric and/or autoinhibited 413 
forms. For example, while KBP does not interact with some target kinesins in 414 
autoinhibited conformations
18
, others that retain a structurally available tubulin-415 
binding subdomain, such as autoinhibited kinesin-3 monomers
45
, are feasible binding 416 
partners. KBP can bind to constitutively active dimeric kinesin constructs that lack 417 
autoinhibitory regions
9,18
, although the stoichiometry and structural details in this 418 
context are unclear. Furthermore, any additional effects of kinesin cargo binding on 419 
their susceptibility to KBP inhibition are not well understood. It will also be of key 420 
importance to elucidate the mechanisms of KBP activity regulation, for example, by 421 
phosphorylation of KBP and/or kinesins
9
 and KBP acetylation and targeted 422 
degradation by the ubiquitin system
46
. Our structural characterisation of the KBP-423 
kinesin inhibitory interaction provides an important mechanistic platform from which 424 
to expand our understanding of KBP’s biological roles in neuronal function and 425 
cancer. 426 
 427 
  428 
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Methods 429 
 430 
Protein expression and purification for cryo-EM 431 
 432 
Full length human KBP residues 1-621 in a PSTCm1 expression vector (with 433 
kanamycin resistance and a N-terminal thrombin cleavable 6 x His-tag) was expressed 434 
in Rosetta2 cells (Novagen) as previously described
9
. Following immobilised metal-435 
affinity chromatography with Ni-NTA resin (Qiagen), the 6 x His-tag was removed 436 
via incubation with thrombin protease overnight at 4 °C. The protein was then 437 
subjected to reverse IMAC and further purified using size exclusion chromatography 438 
(SEC) into a buffer of 20mM TrisHCL (pH7.4), 150mM NaCl, 2.5mM CaCl2, 1mM 439 
DTT. Protein was snap-frozen and stored in at -80 °C. 440 
 A human KIF15 motor domain and neck linker construct (residues 1-375) in a 441 
pET21a vector with a C-terminal 6 x His-tag was generated by chemical synthesis 442 
(GenScript, Piscataway, NJ). Six of the eight cysteine residues (C5S, C50S, C162S, 443 
C294S, C314S, C346S) were mutated and two cysteines were inserted (S250C, 444 
G375C) for orthogonal experiments not described further here. We refer to this 445 
construct as KIF15_MD6S. KIF15_MD6S was expressed and purified using methods 446 
previously described
47
, then buffer exchanged into 25 mM HEPES pH 7.5, 100 mM 447 
KCl, 2 mM MgCl2, 1 mM EGTA, 1 mM DTT, 0.1 mM ATP, snap frozen in liquid 448 
nitrogen and stored at -80ºC.  449 
 A human KIF1A motor domain and neck linker construct (KIF1A_MD residues 450 
1-362) in a pFN18a vector (with a TEV protease-cleavable N-terminal Halo-tag and a 451 
C-terminal 6 x His-tag) was expressed in BL21-Gold (DE3) cells, as previously 452 
described
28
. Following a first IMAC with Ni-NTA resin, the Halo-tag was removed 453 
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via incubation overnight with TEV protease at 4 °C. The protein was then isolated 454 
from TEV via a second IMAC with Ni-NTA resin and further purified by SEC into a 455 
storage buffer of (20 mM HEPES, pH 7, 150 mM NaCl, 5 mM MgCl2, 0.1 mM ADP 456 
and 1 mM TCEP). 457 
 KIF15_MD6S or KIF1A_MD complexes with KBP were purified via IMAC 458 
using the 6 x His tag on the kinesin constructs. Briefly, His-tagged kinesins were 459 
incubated with a 10 times excess of KBP in 20 mM TrisHCL (pH7.5), 150 mM NaCl, 460 
1 mM MgCl2, 10 mM Imidazole, 1 mM DTT, 0.2 mM ADP for 5 minutes at 4 °C. 461 
Following IMAC, complexes were eluted from the Ni-NTA resin (Qiagen) by 462 
addition of 200 mM imidazole, then dialyzed at 4 °C for 4 hours into 20 mM 463 
TrisHCL (pH7.5), 150 mM NaCl, 1 mM MgCl2, 1 mM DTT, 0.2 mM ADP. 464 
 465 
Steady-state ATPase assay 466 
 467 
ATPase activity of KIF15_MD6S was measured in ATPase buffer (50 mM potassium 468 
acetate, 25 mM HEPES, 5 mM magnesium acetate, 1 mM EGTA, pH 7.50) by 469 
measuring phosphate production in the presence of a minimum of a 5-fold molar 470 
excess of paclitaxel-stabilised MTs, using a commercially-available kit (EnzChek, 471 
Molecular Probes) at 20
o
C.   472 
 473 
Sample preparation for cryo-EM 474 
 475 
KBP was prepared for cryo-EM using three different approaches. In the first 476 
approach, KBP was diluted to 0.15 mg/ml in KBP dilution buffer (20 mM TrisHCL, 477 
pH7.5, 150 mM NaCl, 2 mM DTT) and 4 μl were applied to glow-discharged C-478 
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flat
TM
 2/2 holey carbon EM grids (Protochips, Morrisville, NC). For the second 479 
approach, KBP was diluted to 0.3 mg/ml in KBP dilution buffer and 4 μl were applied 480 
to glow-discharged 1.2/1.3 AuFoil gold grids (Quantifoil
®
). For the third approach, 481 
glow-discharged C-flat
TM
 2/2 holey carbon EM grids were coated with graphene-482 
oxide (GO) according to the protocol described by Cheng and colleagues
48
 then 4 μl 483 
of KBP diluted to 0.02 mg/ml in KBP dilution buffer were added. 484 
 Kinesin motor domain-KBP complexes were diluted to 0.03 mg/ml in KBP-485 
kinesin dilution buffer (20 mM TrisHCL (pH7.5), 50 mM NaCl, 1 mM MgCl2, 1 mM 486 
DTT, 0.2 mM ADP) and 4 μl were added to the GO-coated gold grids described 487 
above. After a 30 second incubation of samples on the EM grid in a Vitrobot Mark IV 488 
(FEI Co., Hillsboro, OR) set at 4 °C and 80 % humidity, samples were blotted (6-8 489 
seconds, blot force -10) and vitrified in liquid ethane. All steps were performed at 4 490 
°C. 491 
For preparation of the KIF15_MD6S-MT complex, porcine tubulin (>99% 492 
pure, Cytoskeleton Inc.) was polymerised in MES polymerisation buffer (100 mM 493 
MES, 1 mM MgCl2, 1 mM EGTA, 1 mM DTT, pH 6.5) with 5 mM GTP at 37 °C then 494 
stabilised with 1 mM paclitaxel. ~70 μM KIF15_MD6S was pre-incubated for 5 min 495 
with 5 mM of AMPPNP in BRB80 at room temperature, and then mixed with 20 μM 496 
stabilised MTs. After a further incubation of 15 min, a 4 μl droplet was applied to a 497 
pre-glow discharged holey carbon grid (2/2 C-flat, Protochips Inc.), blotted for 3.5 s 498 
and then vitrified in liquid ethane using a Vitrobot Mark IV at ambient temperature 499 
and 80% humidity. 500 
 501 
Cryo-EM data collection 502 
 503 
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For dataset of KBP alone or KBP-KIF15_MD6S, low-dose movies were collected 504 
automatically using EPU software (Thermo Fisher, MA, USA) on a Titan Krios 505 
electron microscope (Thermo Fisher) operating at 300 kV, with a K2 summit direct 506 
electron detector (Gatan, CA, USA) and a quantum post-column energy filter (Gatan) 507 
operated in zero-loss imaging mode.  508 
 Datasets of KBP alone were collected either at eBIC or the ISMB, Birkbeck 509 
using a Volta phase plate (VPP), a sampling of ~1.05 Å/pixel and a nominal defocus 510 
range of 0.5-0.7 μm. The total dose was 42 e-/Å
2
 over 40 frames, with the detector 511 
operating in counting mode at a rate of ~5 e-/pixel/second. 512 
 Datasets of KBP-kinesin complexes were collected at the ISMB, Birkbeck 513 
without a phase plate and a nominal defocus range of 1.5-4 μm. KIF1A_MD-KBP 514 
complexes were collected at a sampling of 0.85 Å/pixel, whereas KBP-KIF15_MD6S  515 
complexes were collected at a sampling of 1.047 Å/pixel. For KIF1A_MD-KBP 516 
complexes, the total dose was 88 e-/Å
2
 over 36 frames, with the detector operating in 517 
counting mode at a rate of 7.1 e-/pixel/second. For KBP-KIF15_MD6S complexes, 518 
the total dose was 80 e-/Å
2
 over 64 frames, with the detector operating in counting 519 
mode at a rate of 5.7 e-/pixel/second. 520 
 The KIF15_MD6S-MT dataset was collected manually on a Tecnai Polara 521 
microscope (Thermo Fisher) at the ISMB, Birkbeck, operating at 300 kV, with a K2 522 
summit direct electron detector (Gatan, CA, USA) and a quantum post-column energy 523 
filter (Gatan) operated in zero-loss imaging mode. A nominal defocus range of 1.0-3.5 524 
μm and a final pixel size of 1.39 Å was used. The total dose was 32 e-/Å
2
 over 50 525 
frames, with the detector operating in counting mode at a rate of 6.2 e-/pixel/second. 526 
 527 
Cryo-EM data processing 528 
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 529 
Low-dose movies were motion-corrected using MotionCor2
49
 with a patch size of 5, 530 
generating full-dose and dose-weighted sums. CTF determination was performed on 531 
full-dose sums with gCTF
50
 and then dose-weighted sums were used for all further 532 
processing. Data were cleaned at this stage by first excluding all micrographs with 533 
gCTF resolutions worse than 4.5 Å, as estimated with a custom cross-correlation 534 
coefficient cutoff (Python script kindly shared by Radostin Danev), then manually 535 
removing micrographs with poor appearance (ice contamination, protein aggregation 536 
or poor GO coverage) in real or reciprocal space. For KBP alone data, micrographs 537 
with calculated phase shifts outside the expected phase shift progression at each plate 538 
position were also excluded. 539 
 Particles were first picked using Eman2’s neural network picker
51
, with a 180 540 
pixel box size for KBP-alone and KBP-KIF15_MD6S datasets, or a 220 pixel box 541 
size for the KBP-KIF1A_MD datasets. Good 2D classes were then used as templates 542 
to pick the data with Gautomatch (http://www.mrc-lmb.cam.ac.uk/kzhang/). 543 
 For Eman2 neural network picker or Gautomatch-derived particles from each 544 
dataset, separate multiple rounds of 2D classification were performed in RELION 545 
v3.0
52
, cryoSPARC2
53
 or cisTEM
54
. This resulted in a total of six sets of good 2D 546 
classes showing clear secondary structure for each dataset, two produced by each 547 
programme for each picking method. For each dataset, these six good 2D class sets 548 
for each dataset were then combined and duplicate particles removed. At this stage, 549 
for each sample (KBP-alone, KBP-KIF15_MD6S or KBP-KIF1A_MD) good 2D 550 
classes from their constituent datasets were combined. 551 
 KBP-KIF15_MD6S or KBP-KIF1A_MD datasets, composed of their respective 552 
constituent datasets were easily combined, being from the same microscope and 553 
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optical set up. However, KBP-alone data were collected on different microscopes and 554 
had a range of pixel sizes (<2% difference). KBP-alone data therefore was combined 555 
at this stage using the optics grouping protocol in RELION v3.1
52
. 556 
 KBP-alone and KBP-KIF15_MD6S data were taken to 3D processing at this 557 
stage, while multiple attempts to process KBP-KIF1A_MD data in 3D gave no 558 
reliable results. For KBP-alone and KBP- KIF15_MD6S data, de novo initial 3D 559 
models were created in cryoSPARC2. For KBP- KIF15_MD6S data, a single round of 560 
3D classification was performed in RELION v3.0 and the best class selected and 561 
auto-refined. For KBP-alone data, 3D classification in RELION v3.1 or cryoSPARC2 562 
did not reveal different 3D structures or improve reconstructions over sorting only in 563 
2D; therefore, particles selected with 2D classification were used as direct input for 564 
auto-refinement. The final KBP-alone map was sharpened with a B-factor of -200 to 565 
the gold-standard FSC 0.143 cutoff (4.6 Å). The KBP- KIF15_MD6S map was 566 
sharpened locally with a B-factor of -495, according to local resolutions determined 567 
using RELION v3.1’s inbuilt local resolution software. 568 
 The KIF15_MD6S-MT dataset was processed using our MT RELION-based 569 
pipeline (MiRP) as described previously, using low-pass filtered KIF5B_MD-570 
decorated MTs as references 
55,56
. KIF15_MD6S 13-protofilament-MTs were the 571 
most common MT architecture and were selected after supervised 3D classification in 572 
MiRP for analysis. The symmetrised asymmetric unit (KIF15_MD6S plus a tubulin 573 
dimer) was locally sharpened in UCSF Chimera with a B-factor of -134 according to 574 
local resolutions determined using RELION v3.0’s inbuilt local resolution software.   575 
 All displayed 3D molecular representations were made in UCSF Chimera or 576 
ChimeraX software
57,58
. Data collection and model refinement statistics can be found 577 
in Table 1.. 578 
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 579 
Cryo-EM model building and refinement 580 
 581 
Due to low overall homology to available structures in the protein data bank (PDB), 582 
structure prediction of KBP produced poor models with little resemblance to the cryo-583 
EM density. KBP was therefore modelled using a combination of secondary structure 584 
prediction, TPR prediction, fragment homology information, prior knowledge of 585 
right-handed alpha-solenoid proteins and with reference to the cryo-EM density.  586 
TPR motifs were identified in the KBP sequence using the TPRpred server
59
 587 
available in the MPI Bioinformatics Toolkit
60
. Secondary structure predictions using 588 
Raptor X
61
, iTasser
62
, JPred
63
, Spider2
64
, PSSpred
65
 and SOPMA
66
 were then run on 589 
the sequence and consensus between these multiple predictions used to assign likely 590 
α-helical content. To identify regions dispensable for the overall fold and likely 591 
disordered loop regions, disorder prediction was performed with Raptor X and inter-592 
species low homology regions in KBP (from early Metazoans to humans) were 593 
determined via Clustal Omega multiple sequence alignment
67
. Finally, weak 594 
homology models for overlapping fragments of the structure were identified using the 595 
HHpred
68
 server in the MPI Bioinformatics Toolkit. 596 
 With the information described above a sequence alignment was built with KBP 597 
and the following fragment homology model PDBs; 5OJ8, 4A1S, 3QC1, 4NQ0, 598 
4AIF, and 5MX5. This sequence alignment was used as a basis for multiple rounds of 599 
modelling and flexible fitting with Modeller
69
 and Flex-EM
70
 respectively, using α-600 
helical secondary structure restraints. This modelling process was guided by 601 
consistency with the cryo-EM density and secondary structure and TPR predictions 602 
described above. Finally, the structure was refined against the cryo-EM density in 603 
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real-space with 5 macro-cycles in Phenix
71
. All 19 predicted and modelled helices 604 
were accounted for by rod-like cryo-EM density in the reconstruction and at 4.6 Å 605 
resolution, density was discernible for bulky side chains in the TPR regions (Figure 606 
1–figure supplement 1a,b), providing a validation of the assigned sequence 607 
directionality in the fold. 608 
The KBP KIF15_MD6S model was built as follows: the final KBP model 609 
described above and the KIF15_MD x-ray crystallographic model (PDB 610 
code:4BN2
25
) were rigid fitted into the KBP-KIF15_MD6S density in Chimera. 611 
Density for an extended α6-helix and docked neck-linker in KIF15_MD6S were 612 
absent; therefore, Modeller was used to model a short α6-helix and the neck-linker 613 
removed. A model for the L11, α4-helix and L12 region in KIF15_MD6S were then 614 
created using Coot
72
 and Modeller. The model was refined into the cryo-EM density 615 
in real-space using Phenix
7
 with secondary structure restraints. A first refinement of 616 
15 cycles used rigid bodies describing α-helical hairpins in KBP to get a good rough 617 
fit. Following this, the whole complex was further refined without rigid bodies for 618 
another 5 macro-cycles. 619 
The KIF15_MD6S-MT model was built as follows: the KIF15_MD, 620 
KIF11_MD and KIF5B_MD-tubulin x-ray crystallographic models (PDB 621 
codes:4BN2
25,27,73
) were used as homology models in Modeller to build the KIF15 622 
part of the complex. The KIF15_MD6S model and the paclitaxel-MT tubulin dimer 623 
model
74
 were then rigid fitted into KIF15_MD6S -MT density, combined then refined 624 
in real-space with 5 macro-cycles in Phenix with peptide backbone restraints. 625 
  626 
Antibodies, reagents and expression constructs for cell biology 627 
 628 
 27 
The following antibodies were used for immunofluorescence staining: mouse anti-HA 629 
(1:500, Roche), and goat-anti-mouse Alexa 488 (1:400, Thermo Fisher Scientific). 630 
The following antibodies were used for western blot: mouse anti-HA (1:2,000, 631 
BioLegend), rabbit anti-GFP (1:10,000, Abcam), goat anti‐mouse IRDye800CW 632 
(1:15.000, LI‐COR), and goat‐anti‐rabbit IRDye680LT (1:20,000, LI‐COR). A 633 
reagent used in this study is rapalog (AP21967, TaKaRa). 634 
 The following DNA expression constructs in this study have been described 635 
before: GW1-PEX3-mRFP-FKBP1, βactin-Kif1A_MDC-FRB
9
 (mouse cDNA), BirA 636 
coding vector
75
 and pebioGFP
75
. pGW1-HA-KBP contained a linker 637 
(GGATCCCCGGAATTCGGCACGAGGGAGGCCGCT) between the HA tag and 638 
KBP and was cloned using PCR based strategies with human KBP cDNA 639 
(KIAA1279, IMAGE clone 4550085) as template and ligation into the pGW1-HA 640 
backbone. A similar strategy was used to generate the mutated KBP constructs, listed 641 
in Table 2. βactin-KIF15_MDC-FRB was cloned using a PCR based Gibson 642 
Assembly strategy with mouse KIF15 cDNA as template into the βactin-643 
KIF1A_MDC-FRB backbone. PebioGFP-KIF1A_MDC and pebioGFP-KIF15_MDC 644 
were cloned into the pebioGFP backbone using PCR based strategies with MDC-FRB 645 
constructs as templates. 646 
 647 
Cell culture, transfection and immunofluorescence staining 648 
 649 
COS-7 cells were purchased from ATCC and routinely checked for mycoplasma 650 
contamination using LT07-518 Mycoalert assay (Lonza). Cells were cultured in 50/50 651 
DMEM (Lonza)/Ham's F10 (Lonza) medium supplemented with 10% FCS (Sigma) 652 
and 1% penicillin/streptomycin (Sigma). One day before transfection cells were 653 
 28 
diluted and plated on 18-mm glass coverslips. COS-7 cells were transfected using 654 
FuGENE6 (Roche) following the manufacturer’s protocol. Next day, rapalog (final 655 
concentration 1 µM) was added and cells were incubated for 3 hours. Cells were then 656 
fixed with 4% formaldehyde/4% sucrose in phosphate-buffered saline (PBS) for 10 657 
minutes at room temperature, washed three times PBS-CM (PBS supplemented with 1 658 
mM MgCl2 and 0.1 mM CaCl2), permeabilized in 0.2% TritonX-100 for 15 minutes  659 
and washed one time with PBS-CM. Cells were first incubated with 0.2% gelatin for 660 
30 minutes at 37 ℃, and then with primary antibodies, diluted in 0.2% gelatin, for 30 661 
minutes at 37 ℃. After washing three times with PBS-CM, cells were incubated for 662 
30 minutes at 37 ℃ with secondary antibody diluted in 0.2% gelatin, washed three 663 
times in PBS-CM, and finally mounted using Fluoromount (Invitrogen). 664 
 665 
Cell biology image analysis and quantification 666 
 667 
Fixed cells were imaged on a Carl Zeiss LSM 700 confocal laser scanning microscope 668 
running ZEN2011 software, using a Plan-Apochromat 40x/1.30 oil DIC objective and 669 
image settings were maintained the same for all images within one experiment. 670 
Images were acquired of cells that express similar levels of HA-KBP constructs based 671 
on immunostaining (Figure 5 – figure supplement 1). Cells were selected on a first-672 
come-first served basis. Images were processed and analysed using Fiji software
76
. To 673 
calculate the percentage of cells in which translocation of peroxisomes was observed, 674 
imaged cells were classified as either translocating, when peroxisomes re-localized 675 
into the cell periphery, or not translocating, when peroxisomes remained in the cell 676 
centre. For quantification of PEX translocation, an ROI of the cell area was drawn 677 
and from this a second ROI at 5 (KIF1A_MDC) or 7.5 (KIF15_MDC) µm from the 678 
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outer cell area was created. Images were thresholded at 7500 (KIF15_MDC) or 10000 679 
(KIF1A_MDC). Different peripheral areas and threshold values were defined for the 680 
two kinesins, due to observed differences in translocation properties between the 681 
kinesins (compare Figure 5 – figure supplement 3a-c). For the two selected ROIs, the 682 
area with fluorescent intensity above threshold was determined in the RFP channel. 683 
From these values the percentage of cell area above threshold in the cell periphery 684 
from the total area above threshold was calculated.   685 
 686 
Pull-down experiments and western blotting 687 
 688 
HEK293T cells were purchased from ATCC and routinely checked for mycoplasma 689 
contamination using LT07-518 Mycoalert assay (Lonza). Cells were cultured in 50/50 690 
DMEM (Lonza)/Ham's F10 (Lonza) medium supplemented with 10% FCS (Sigma) 691 
and 1% penicillin/streptomycin (Sigma). One day before transfection cells were 692 
diluted and plated into 6-well plates. Cells were co-transfected with pCl-Neo-BirA, 693 
HA-tagged constructs and bioGFP-tagged constructs using MaxPEI (Polysciences) in 694 
a ratio of 3/1 PEI/DNA, according to the manufacturer’s protocol. After 24-hours of 695 
expression, cells were washed in ice-cold PBS and lysed in lysis buffer (100 mM 696 
TrisHCl pH 7.5, 150 mM NaCl, 1% Triton X-100, protease inhibitors (Roche)) for 30 697 
minutes on ice. Lysates were cleared by 30-minute centrifugation at 13.2 krpm at 4℃ 698 
and supernatants were incubated with blocked (incubation for 30 minutes at RT in 50 699 
mM Tris–HCl pH 7.5, 150 mM KCl, 0.2 μg/μl chicken egg albumin) Streptavidin 700 
Dynabeads M-280 (Invitrogen) for 1.5 hours at 4℃. Beads were then washed five 701 
times with washing buffer (100 mM Tris–HCl pH 7.5, 250 mM NaCl, 0.5% Triton X‐702 
100) and proteins were eluded from the beads by boiling for 10 minutes at 95℃ in 2x 703 
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DTT+sample buffer (20% glycerol, 4% SDS, 200 mM DTT, 100 mM Tris–HCl pH 704 
6.8, bromophenol blue). 705 
 Protein samples were run on 10% SDS-PAGE gels and transferred to 706 
nitrocellulose membranes (Bio-Rad) by semi-dry blotting at 16V for 1 hour. 707 
Membranes were blocked by incubation in 3% bovine serum albumin (BSA) in PBST 708 
(PBS supplemented with 0.02% Tween20) for 1 hour at room temperature. This was 709 
followed by overnight incubation with primary antibodies in 3% BSA-PBST. 710 
Membranes were washed three times with PBST, incubated with secondary antibody 711 
in 3% BSA-PBST for 1 hour at room temperature, and washed three times with 712 
PBST. Membranes were scanned using an Odyssey Infrared Imaging system (LI‐COR 713 
Biosciences) and blots were acquired at 680 nm and 800 nm. 714 
 715 
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Figures 961 
 962 
Figure 1. KBP is a TPR-containing right-handed α-solenoid. 963 
(a) Model of KBP (ribbon representation) displayed in experimental cryo-EM density. 964 
The N-terminal (olive) and C-terminal (gold) subdomains are separated by a linker 965 
region (black). Semi-transparent density is coloured regionally as per the fitted model. 966 
The N- and C-termini are shown, with a dotted line representing the disordered C-967 
terminus (not modelled). The linker loop region was not modelled but its density is 968 
shown in semi-transparent black. (b) The same as panel a, but rotated 180 around the 969 
axis indicated. (c) The same view as in panel a, but with the density removed and -970 
helices displayed as pipes with their directionality indicated by arrows. The 9 971 
antiparallel -helical pairs (HP1 to HP9) are each coloured separately and labelled, 972 
as is the linker -helix (LH) and linker loop (LL, dotted line). (d) Ribbon 973 
representation of KBP showing the 4 tetratrico peptide repeat (TPR) motifs and the 974 
LH coloured according to the labels. View related to panel c, by a 90 rotation 975 
around the indicated axis. (e) Schematic of the KBP showing the position of the TPR 976 
motifs between residue 95 and 283 of the N-terminal subdomain and position of the 977 
linker region (LH and LL) between residues 305 and 392. 978 
 979 
Figure 2. KBP conformationally adapts to bind KIF15’s motor domain via both 980 
subdomains 981 
(a) Model of the KBP-KIF15_MD6S complex (ribbon representation) displayed in 982 
experimental cryo-EM density. The N-terminal (olive) and C-terminal (gold) 983 
subdomains and the linker helix (black) are shown in KBP, while kinesin is coloured 984 
in magenta. Semi-transparent density is coloured regionally as per the fitted model 985 
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and additional density for the linker loop is shown in semi-transparent black. (b) The 986 
same as panel a, but rotated 180 around the axis indicated. (c) The KBP-alone model 987 
(light grey ribbons) was superimposed on the KBP-KIF15_MD6S model (opaque 988 
ribbons) using Chimera’s matchmaker
57
. Colouring and view as in panel b. (d) RMSD 989 
in Å for KBP comparing KBP-KIF15_MD6S and superimposed KBP-alone models 990 
as in panel c, shown on KBP from the KBP- KIF15_MD6S model. Parts of the KBP 991 
model coloured black are disordered/missing in the KBP alone model. The 992 
KIF15_MD6S is shown in transparent magenta. 993 
 994 
Figure 3. The KIF15 motor domain binds KBP via rearrangement of its tubulin-995 
binding subdomain. 996 
(a) The crystallographic model of the KIF15_MD alone (PDB: 4BN2
25
) was 997 
superimposed on the KIF15 region of the KBP-KIF15_MD6S complex, with the 998 
KIF15 part of the KBP- KIF15_MD6S complex model hidden. The KIF15_MD6S 999 
Switch 1/2 subdomain (Switch 1/2 subdomain) is coloured sienna, the P-loop 1000 
subdomain (Kin-PLsd) is coloured light pink. The TBsd of the KIF15_MD 1001 
crystallographic model is shown as pale magenta to illustrate poor fit into density. 1002 
The KBP subdomains are coloured as labelled.  Black arrows indicate unaccounted-1003 
for cryo-EM density. Individual secondary structure elements in the tubulin-binding 1004 
subdomain are labelled. The cryo-EM density for the KBP-KIF15_MD6S complex is 1005 
shown in mesh and is coloured by proximity (≤ 3.5 Å) to the fitted model. (b) Same as 1006 
in panel a, but the whole fitted KBP-KIF15_MD6S complex model is shown. The 1007 
KIF15_MD6S tubulin-binding subdomain (TBsd) is now coloured magenta to 1008 
indicate good fit into density. (c) Zoomed view of just the TBsd (corresponding to the 1009 
boxed region in Figure 3–figure supplement 2d), showing just the KIF15_MD-alone 1010 
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crystallographic model. (d) The TBsd in the KIF15_MD6S-MT model, same view as 1011 
in panel c. The MT is shown in light grey surface representation. (e) The TBsd in the 1012 
KBP-KIF15_MD6S model, same view as in panel c. KBP is shown in light grey 1013 
surface representation and the ~15 Å displacement of helix α4 is indicated by the 1014 
dashed grey arrow. 1015 
 1016 
Figure 4. KBP binds kinesin MDs via conserved motifs in the α-solenoid edge 1017 
loops and α-helices at the concave face. 1018 
(a) Pseudo-atomic model of the KBP-KIF15_MD6S complex (ribbon representation) 1019 
displayed in cryo-EM density, using the same viewpoint as Figure 2a, but with the 1020 
KIF15_MD6S now coloured by subdomain as in Figure 3. The KIF15_MD6S Switch 1021 
1/2 subdomain (Kin S1/2 sd) is coloured sienna, the P-loop subdomain (Kin-PLsd) is 1022 
coloured light pink. The KIF15_MD6S tubulin-binding subdomain (TBsd) is coloured 1023 
magenta. The KBP subdomains are coloured as labelled. The nine helix pairs of KBP 1024 
are labelled. Semi-transparent density is coloured regionally as per the fitted model 1025 
and additional density for the linker loop is shown in semi-transparent black. (b) The 1026 
same as panel a, but rotated 45 and 15 respectively around the axes indicated. (c) 1027 
Zoomed view of the region indicated in panel a, with density removed and selected 1028 
KIF15_MD6S and KBP secondary structure elements labelled. (d) Zoomed view of 1029 
the region indicated in panel b, with density removed and selected KIF15_MD6S and 1030 
KBP secondary structure elements labelled.  1031 
 1032 
Figure 5. Disruption of cryo-EM defined KBP-kinesin interface perturbs KBP 1033 
inhibition of KIF15 and KIF1A-mediated cargo translocation in cells.  1034 
 40 
(a) Schematic depiction of the inducible peroxisome motility assay, with the kinesin 1035 
motor domain fused to an FRB domain and PEX fused to an FKBP domain. Addition 1036 
of rapalog (Rap) links FRB and FKBP and induces peroxisome translocation by 1037 
kinesin dimers. Expression of KBP inhibits kinesin movement, such that addition of 1038 
rapalog cannot induce peroxisome translocation. (b) Schematic representation of the 1039 
inducible peroxisome motility assay in cells. Without rapalog or KBP, peroxisomes 1040 
localize in the cell center, whereas kinesin moves towards the cell periphery. Rapalog 1041 
induces peroxisome translocation into the cell periphery, which is inhibited in 1042 
presence of KBP. (c) Representative images of peroxisomes in COS-7 cells 1043 
expressing KIF15_MDC-FRB, PEX-mRFP-FKBP and HA (left panels) or HA-KBP 1044 
(right panels) without and with addition of rapalog . Scale bar, 10 µm. (d, e) 1045 
Quantification of the percentage of cells in which peroxisome translocation is 1046 
observed after rapalog treatment in cells expressing KIF15_MDC-FRB (d) or 1047 
KIF1A_MDC-FRB (e), PEX-mRFP-FKBP, and HA-KBP constructs including the 1048 
indicated mutants. Data are displayed as mean ± s.e.m. (n=28-35 cells from two 1049 
independent experiments). (f, g) Quantification of the area above threshold intensity 1050 
in the outer 5 µm (KIF1A_MDC) or 7.5 µm  (KIF15_MDC) of the cell from the total 1051 
area above threshold intensity in cells expressing KIF15_MDC-FRB (f) or 1052 
KIF1A_MDC-FRB (g), PEX-mRFP-FKBP, and HA-KBP constructs including the 1053 
indicated mutants without and with rapalog treatment. Data are displayed as mean ± 1054 
s.e.m. (n=28-35 cells from two independent experiments).  1055 
 1056 
Figure 6. Conserved motifs in KBP-binding kinesin MDs. 1057 
(a) Sequence alignment of the tubulin-binding subdomain from kinesin motor 1058 
domains, made using Clustal Omega multiple sequence alignment
67
. Residues are 1059 
 41 
coloured according to standard Clustal X colouring (dependent on residue type and 1060 
conservation, see 1061 
http://bioinfolab.unl.edu/emlab/documents/clustalx_doc/clustalx.html#C). Kinesin 1062 
MD constructs experimentally assessed for KBP interactivity are taken from
9
; 1063 
strongest interactors are in rows highlighted in darker shades of green, weaker 1064 
interactors in lighter shades of green and non-interactors in red. Secondary structure 1065 
element, conservation and charge variation columns, as well as a ‘binding consensus’ 1066 
column indicating residues/loop length conserved at the interface (according to the 1067 
KBP-KIF15_MD6S complex) in KBP-binding but not non-binding kinesins are 1068 
shown above the alignment. Non-conservation relative to this consensus is shown in 1069 
boxed sequence; red boxes, non-conservative substitutions, orange boxes, 1070 
conservative substitutions (general charge/polarity/hydrophobicity retention), cyan 1071 
boxes, extended loop region, dark blue boxes, truncated loop region. (b) Top panel; 1072 
view of the K4-KL8 region of the tubulin-binding subdomain in the KBP- 1073 
KIF15_MD6S model, coloured as in Figure 4. Bottom panel; as in upper panel, but 1074 
with the KIF11_MD cryo-EM model (PDB: 6TA4
77
) superimposed onto the now 1075 
hidden KBP-KIF15_MD6S. Note steric clash introduced by KIF11_MD’s extended 1076 
KL8. c) Schematic model of KBP’s hypothesised selective kinesin inhibition 1077 
mechanism. KBP (olive) binds the compatible TBsd of recognised kinesins (magenta) 1078 
but is incompatible with the TBsd of non-binding kinesins (salmon). For its target 1079 
kinesins, KBP therefore sterically blocks the TBsd interaction with MTs (grey), 1080 
preventing activation of kinesin ATPase and motility.  1081 
 1082 
Figure 1–figure supplement 1. KBP reconstruction, structure and loop lengths. 1083 
 42 
(a) Gold-standard FSC curves between independent masked, unmasked, phase-1084 
randomised and corrected half-maps
78
 of KBP as calculated by RELION v3.1
52
 (4.6 Å 1085 
resolution at the ‘gold-standard’ 0.143 FSC cutoff). (b) Density and fitted model for 1086 
TPR3 of KBP, showing exemplar bulky side chain density that guided modelling. (c) 1087 
Same view as Figure 1c (upper panel), or rotated 90 around the indicated axis (lower 1088 
panel), showing only -helices (semi-transparent white tubes) with their terminal 1089 
residues coloured, illustrating the edges and faces (concave and convex) of the -1090 
solenoid respectively. (d) Same view as panel c, but now with loops shown and 1091 
coloured (semi-transparent tube helices have their directionality represented by 1092 
arrows). Each loop or terminus label has a superscript number indicating their length. 1093 
(e) Same as panel d, rotated 180 around the indicated axis.  1094 
 1095 
Figure 1–figure supplement 2. KBP loops, sequence, inter-species conservation 1096 
and experimental mutations. 1097 
The human KBP sequence (numbering above), with residues coloured by intra-1098 
species sequence identity as indicated in the key. The following species were included 1099 
in the Clustal Omega multiple sequence alignment
67
; Homo sapiens, Mus musculus, 1100 
Gallus gallus, Xenopus tropicalis, Alligator mississippiensis, Danio rerio, Drosophila 1101 
melanogaster, Amphimedon queenslandica, Stylophora pistillata, Trichoplax 1102 
adhaerens, Spizellomyces punctatus and Salpingoeca rosetta. Above the sequence, 1103 
secondary structure elements are indicated, coloured to delineate the nine -helical 1104 
pairs and connecting loops. Mutation sites are indicated within each boxed sequence 1105 
region, labelled to coordinate with Figure 5. Within these boxes, the mutated 1106 
sequence is shown below the original wild-type sequence. 1107 
 1108 
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Figure 1–figure supplement 3. Approximate path of the KBP linker loop. 1109 
View of KBP’s linker loop, using the same KBP model subdomain colouring and 1110 
representation as in Fig. 1a-b. Only density for the linker loop is shown and a rough 1111 
path for the linker loop is indicated with a solid black line. KBP -helices contacting 1112 
the linker loop region are labelled.  1113 
 1114 
Figure 2–figure supplement 1. KBP-KIF15_MD6S reconstruction resolution 1115 
estimation and 2D class analysis of KBP-KIF1A_MD and KBP-KIF15_MD 1116 
complexes. 1117 
(a) KIF15_MD6S MT-activated steady-state ATPase velocity plotted as a function of 1118 
[MT]. Data were fit to a Michaelis Menten kinetic (pink curve) yielding values for 1119 
kcat = 2.9 ± 0.5 sec-1 and K0.5,MT = 4.8 ± 1.4 M; R
2
 = 0.97, which are very similar 1120 
to previously published values for KIF15_MD of kcat = 2.1 sec-1 and K0.5,MT = 3.1 1121 
M
25
. (b) Gold-standard FSC curves between independent masked, unmasked, phase-1122 
randomised and corrected half-maps
78
 of the KBP-KIF15_MD6S complex as 1123 
calculated by RELION v3.0
52
. The resolution at the ‘gold-standard’ 0.143 FSC cutoff 1124 
is 6.9 Å. (c) Local resolution as calculated by RELION v3.0, shown on the same view 1125 
as in Figure 2a with coloured density corresponding to the local resolutions indicated 1126 
in the key. (d) Selected RELION v3.0
52
 2D classes of KBP-KIF15_MD6S (left) and 1127 
KIF1A_MD-KBP (4 to the right). Densities for the kinesin motor domain and KBP 1128 
are pseudo-coloured pale magenta and pale orange respectively. Classes have been in-1129 
plane rotated such that KBP is seen from roughly the same orientation. Note poor 1130 
resolution and a variable relative position in the KIF1A_MD. (d) A representative 1131 
subset of KBP-KIF15_MD6S complex 2D classes, showing multiple orientations. 1132 
 1133 
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Figure 3–figure supplement 1. KIF15_MD6S adopts a canonical MT-bound 1134 
kinesin conformation. (a) Gold-standard FSC curves between independent masked, 1135 
unmasked, phase-randomised and corrected half-maps
78
 of the KIF15_MD6S-MT 1136 
complex as calculated by RELION v3.0
52
. The resolution at the ‘gold-standard’ 0.143 1137 
FSC cutoff is 4.5 Å. (b) Local resolution as calculated by RELION v3.0, with 1138 
coloured density corresponding to the local resolutions indicated in the key. (c) The 1139 
KIF15_MD6S-MT asymmetric unit model in corresponding density. The 1140 
KIF15_MD6S is coloured by subdomain, bound Mg2+-AMPPNP coloured lilac and  1141 
and β-tubulin are coloured light and dark grey respectively, along with their 1142 
corresponding cryo-EM densities. The same view as in panel b. (d) A view of the 1143 
KIF15_MD6S-MT asymmetric unit showing a docked conformation of the neck-1144 
linker (KNL). Model and density colouring as in panel c. (e) The tubulin binding 1145 
subdomain of KIF15_MD alone from the crystal structure (PDB code:4BN2
25
). (f) 1146 
KIF15_MD6S complexed with MTs with only the tubulin-binding subdomain and  1147 
and β-tubulin shown, along with the tubulin binding subdomain cryo-EM density 1148 
(semi-transparent). K4 of KIF15_MD6S is extended relative to the crystal structure 1149 
and KL12 adopts a new conformation on -tubulin, as indicated by the green dashed 1150 
lines. Panels d and e show the KIF15_MD6S tubulin-binding subdomain from the 1151 
same viewpoint. 1152 
 1153 
Figure 3–figure supplement 2. Movement of K4 of the Kin TBsd upon KBP 1154 
binding. 1155 
(a) The KIF15_MD alone crystal structure (PDB code:4BN2
25
) is shown coloured by 1156 
kinesin subdomain (as in Figure 3), fitted into the KBP-KIF15_MD6S complex cryo-1157 
EM map, with only density shown for the Mg2+-ADP as mesh. Density for Mg2+-ADP 1158 
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is found in the expected position between nucleotide binding elements KL9, KL11, 1159 
K2a and the P-loop. (b) As in Figure 3a, but with a clipped viewpoint zoomed on the 1160 
TBsd (in pale magenta to illustrate poor fit). Black arrows indicate unaccounted-for 1161 
density. (c) As in Figure 3b, with the clipped viewpoint as in panel b of this figure 1162 
(TBsd now opaque to illustrate good density fit). (d) The KBP-KIF15_MD6S model 1163 
is shown as opaque ribbons, with kinesin subdomain colouring as in panel a and b and 1164 
as labelled. KBP is shown as a transparent light grey surface representation. The 1165 
boxed region indicates that shown in Figure 3c-e. (e) RMSD in Å corresponding to 1166 
the KIF15_MD6S overlay in panel d, shown on the model of KIF15_MD6S in 1167 
complex with KBP (grey transparent surface). Parts of the model coloured black are 1168 
disordered/missing in the KIF15_MD alone crystal structure.  1169 
 1170 
Figure 3–figure supplement 3. Examples of TPR-containing -solenoid proteins 1171 
binding -helical SSE ligands. 1172 
(a-d) Comparison of (a) KBP- KIF15_MD6S complex with other TPR-containing -1173 
solenoids shown in blue, and binding peptide motifs shown in magenta or pink for 1174 
helical and random coil regions respectively; (b) the PINS-INSC complex
30
, (c) the 1175 
CDC16-CDC26 complex
31
 and (d) the PscE/PscG-PscF complex
32
. 1176 
 1177 
Figure 4–figure supplement 1. Additional KBP α-solenoid edge loops proximal to 1178 
KIF15_MD6S. 1179 
Colouring and representation as in Figure 4. (a) A view showing -helical pairs 1180 
HP1, HP2, HP3, HP8 and HP9 of KBP and the KIF15_MD6S coloured by 1181 
subdomain as labelled. (b) Left zoomed region in panel a, with density removed, 1182 
showing KBP L1, L3, L5 and proximal kinesin elements KL9, KL11 and K6. ADP 1183 
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is coloured in light orchid. (c) Right zoomed region in panel a, with density removed, 1184 
showing KBP L16 and L18 and proximal KIF15_MD6S elements KNT (kinesin N-1185 
terminus), KNL (kinesin neck-linker) and KL12. 1186 
 1187 
Figure 5–figure supplement 1. KBP mutants show similar expression profiles in 1188 
COS-7 cells.  1189 
(a) Representative images of COS-7 cells expressing HA-KBP mutant constructs. 1190 
Scale bar, 10 µm. 1191 
 1192 
Figure 5–figure supplement 2. Pull-down experiments demonstrate the effect of 1193 
KBP mutation on the interaction between KIF15 and KIF1A.  1194 
(a) Control pull-down experiment with bioGFP-EV, bioGFP-KIF1A_MDC or 1195 
bioGFP-KIF15_MDC and HA-KBP showing that KBP interacts with KIF1A_MDC 1196 
and KIF15_MDC, but not with bioGFP-EV. (b, c) Example of pull-down experiments 1197 
showing the interaction between (b) KIF15_MDC or (c) KIF1A_MDC and mutated 1198 
KBP constructs in HEK293T cell lysates. Graphs show the quantification of the 1199 
intensity of the mutated HA-KBP construct in the pull-down fraction over the input 1200 
fraction divided by the intensity of bioGFP_MDC in the pull-down fraction and 1201 
normalized to HA-KBP. Data are displayed as mean ± s.e.m. (data from two 1202 
independent experiments). 1203 
 1204 
Figure 5–figure supplement 3. Kinesin motors show different properties in the 1205 
peroxisome assay. 1206 
(a, b, c) Representative images of peroxisomes in COS-7 cells expressing 1207 
KIF1A_MDC (a) or KIF15_MDC-FRB (b, c), PEX-mRFP-FKBP and HA (left 1208 
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panels) with addition of rapalog. Images were thresholded at 10000 (a, b) or 7500 (c) 1209 
and peripheral areas of 5 µm (a, b) or 7,5 µm (c) are shown. Scale bars, 10 µm.  1210 
 1211 
Video 1. KBP undergoes conformational change to relieve clashes when forming 1212 
a complex with KIF15_MD6S.  1213 
The KBP-alone model was superimposed on the KBP- KIF15_MD6S model using 1214 
UCSF Chimera’s matchmaker
57
. A conformational morph movie was then generated 1215 
in Chimera between the KBP-alone and KIF15 motor domain bound states, with 1216 
KIF15_MD6S shown throughout to illustrate the relief of clashes. The N-terminal and 1217 
C-terminal subdomains are coloured in olive and gold respectively, as in Figure 2a,b, 1218 
while KIF15_MD6S is shown in pale magenta. Distances between identified clashing 1219 
atoms when KBP-alone is superimposed onto the KBP- KIF15_MD6S model are 1220 
indicated by red linking lines and KBP clashing residues and side chains shown in 1221 
cyan. Atoms that were clashing remain coloured while the red lines gradually 1222 
disappear as the clashes are relieved by the conformational change. Clashes were 1223 
calculated in Chimera using default criteria. 1224 
 1225 
Video 2. Interaction of KBP with the KIF15 motor domain. 1226 
Model of the KBP- KIF15_MD6S complex (ribbon representation) displayed in 1227 
experimental cryo-EM density. The N-terminal (olive) and C-terminal (gold) 1228 
subdomains and the linker region (black) are shown in KBP, while the KIF15_MD6S 1229 
Switch 1/2 subdomain (Switch 1/2 subdomain) is coloured sienna, the P-loop 1230 
subdomain (Kin-PLsd) is coloured light pink and the Kif15_MD tubulin-binding 1231 
subdomain (TBsd) is coloured magenta. Semi-transparent density is coloured 1232 
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regionally as per the fitted model and additional density for the linker loop is shown 1233 
in semi-transparent black.  1234 
 1235 
  1236 
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Table 1. Cryo-EM reconstruction information and model refinement statistics and 1237 
model geometry. Data collection, processing and model refinement information for the KBP, 1238 
KBP- KIF15_MD6S and KIF15_MD6S-MT datasets. 1239 
 KBP 
(EMDB: EMD-
11338, PDB: 
6ZPG) 
KBP-
KIF15_MD6S 
(EMDB: EMD-
11339 , PDB: 
6ZPH) 
KIF15_MD6S-
MT 
(EMDB: EMD-
11340, PDB: 
6ZPI) 
Data collection and processing    
Pixel size (Å)* 1.055, 1.043 or 
1.047 
1.047 1.39 
Number of micrographs 
(collected, final)* 
9360, 7547 6497, 5138 214,202 
Final particle number 258,049 (81,628 
of which on 
graphene oxide) 
7,513 12,674 
Map resolution (Å) 
FSC threshold† 
4.6 
Independent 
half-map FSC 
0.143 
6.9 
Independent 
half-map FSC 
0.143 
4.5 
Independent 
half-map FSC 
0.143 
    
Refinement    
Refinement resolution (Å) 
CC_mask‡ 
4.6 
0.64 
6.9 
0.74 
6 
0.60 
Map sharpening B-factor (Å2) -200 -495 -134 
Model composition 
    Nonhydrogen atoms 
    Protein residues 
    Ligands 
 
3,808 
610 
0 
 
6,232 
948 
1 
 
9,420 
1185 
4 
R.m.s. deviations§ 
    Bond lengths (Å) 
    Bond angles (°) 
 
0.01 
0.96 
 
0.01 
1.07 
 
0.08 
0.17 
 Validation# 
    MolProbity score 
    Clashscore 
    Poor rotamers (%)    
 
1.66 
5.25 
0.5% 
 
1.84 
7.31 
0.9% 
 
1.95 
13.25 
0.1% 
Ramachandran plot# 
    Favored (%) 
    Allowed (%) 
    Outliers (%) 
 
94.38 
5.62 
0 
 
93.13 
6.87 
0 
 
95.38 
4.62 
0 
*Inclusive of all data collection sessions 1240 
†The resolution value at the gold-standard Fourier Shell Correlation (FSC) 0.143 criterion 1241 
between independently refined half-maps.  1242 
‡Cross-correlation provided by Phenix real-space refine
7
. 1243 
§Root-mean-square deviations of bond lengths or angles in the model. 1244 
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#As defined by the MolProbity validation server79.  1245 
 51 
Table 2. KBP mutants used in this study. The original and mutated amino acid (top) and 1246 
nucleotide sequences (bottom) are shown for each construct. 1247 
 1248 
Construct Original sequence Mutated to 
L1 EKEPYK 
gagaaggaaccatacaag 
AAAPAA 
gcagcagcaccagcagca 
L3 TEE 
acggaggag 
AGG 
gcaggagga 
L5 REE 
agagaagaa 
AGA 
gcaggagca 
L10 KISATEDTPEAEGEVPEL 
aagatctcagccacagaagacactcctgaagctgaaggagaagtgccagagctt 
AGAGAGAGPAGAGAGPGG 
gcaggagcaggagcaggagcaggaccagcaggagcaggagcaggaccaggagga 
L12 DGY 
gatggttat 
GGA 
ggcggcgcg 
L14 DLNPQY 
gacctgaatccacagtat 
AAGPAA 
gcagcaggaccagcagca 
L16 NKVFPEHIGEDVL 
aataaagtattccctgagcatataggggaagatgttctt 
AAGAPAGAGAGAA 
gcagcaggagcaccagcaggagcaggagcaggagcagca 
L18 EKHPE 
gaaaagcatcctgag 
AAGPG 
gcagcaggaccagga 
αHP4a YLAQ 
tacctagctcaa 
ALAA 
gcactagctgca 
αHP4b Q 
cag 
A 
gca 
αHP5a TLSQ 
accttgtcacag 
ALSA 
gcgttgtcagcg 
 1249 
  1250 
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 1251 
Key Resources Table 
Reagent type 
(species) or 
resource 
Designation 
Source or 
reference 
Identifiers 
Additional 
information 
gene (Homo 
Sapiens) 
 
KIAA1279 GenBank HGNC:23419 
 
gene (Mus 
musculus) 
KIF1A GenBank MGI:108391  
gene (Mus 
musculus) 
KIF15 GenBank 
MGI:109825
8 
  
strain, strain 
background 
(Escherichia 
coli) 
BL21(DE3) NEB Cat. #: 
C2527H 
Competent 
cells 
strain, strain 
background 
(Escherichia 
coli) 
BL21-Gold 
(DE3) 
Agilent Cat. #: 
230130 
Competent 
cells 
strain, strain 
background 
(Escherichia 
coli) 
Rosetta2 
(DE3) 
Novagen Cat. #: 71400 Competent 
cells 
cell line 
(Homo 
Sapiens) 
Human 
embryonic 
kidney 239T 
(HEK293T) 
ATCC 
CRL-3216 
RRID:CVCL
_0063 
  
cell line 
(Cercopithecus 
Aethiops) 
Cercopithecu
s aethiops 
kidney (COS-
7) 
ATCC 
CRL-1651 
RRID:CVCL
_0224 
 
peptide, 
recombinant 
protein 
porcine 
tubulin 
(>99% pure) 
Cytoskeleton 
Inc. 
Cat. #: T240 
 
antibody 
anti-HA 
(Mouse 
monoclonal) 
Roche 
Cat# 
11666606001
; 
RRID:AB_51
IF (1:500) 
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4506 
antibody 
anti-mouse 
IgG1, 
Alexa488 
(Goat 
polyclonal) 
Thermo 
Fisher 
Scientific 
Cat# A-
21121, 
RRID:AB_25
35764 
IF (1:400) 
antibody 
anti-HA 
(Mouse 
monoclonal) 
Biolegend 
Cat# 901533; 
RRID:AB_28
01249 
WB (1:2000) 
antibody 
anti-GFP 
(Rabbit 
polyclonal) 
 Abcam 
  
 
Cat# ab290; 
RRID:AB_3033
95 
 
WB (1:10000) 
antibody 
anti-Rabbit 
IgG Antibody, 
IRDye 680LT 
Conjugated 
(Goat 
polyclonal) 
LI-COR 
Biosciences 
Cat# 827–
11081; 
RRID:AB_10
795015 
WB (1:20000) 
antibody 
anti-Mouse 
IgG Antibody, 
IRDye 800CW 
Conjugated 
(Goat 
polyclonal) 
LI-COR 
Biosciences 
Cat# 827–
08364; 
RRID:AB_10
793856 
WB (1:15000) 
recombinant 
DNA reagent  
KBP (plasmid) 
Kevenaar et 
al., 2016 
 
Described in 
Materials and 
methods 
recombinant 
DNA reagent  
KIF1A_MD 
(plasmid) 
Atherton et 
al., 2014 
 
Described in 
Materials and 
methods 
recombinant 
DNA reagent  
KIF15_MD  
(plasmid) 
This study   
Described in 
Materials and 
methods 
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recombinant 
DNA reagent  
pebioGFP 
(plasmid) 
Van der Vaart 
et al., 2013 
N/A 
Described in 
Materials and 
methods 
recombinant 
DNA reagent  
BirA coding 
vector 
(plasmid) 
Van der Vaart 
et al., 2013 
N/A 
Described in 
Materials and 
methods 
recombinant 
DNA reagent  
GW1-PEX3-
mRFP-FKBP1 
(plasmid) 
Kevenaar et 
al., 2016 
N/A 
Described in 
Materials and 
methods 
recombinant 
DNA reagent  
βactin-
Kif1A_MDC-
FRB 
(plasmid) 
Kevenaar et 
al., 2016 
N/A 
Described in 
Materials and 
methods 
recombinant 
DNA reagent  
βactin-
Kif15_MDC-
FRB 
(plasmid) 
This study N/A 
Described in 
Materials and 
methods 
recombinant 
DNA reagent  
pebioGFP-
Kif1A_MDC 
(plasmid) 
This study N/A 
Described in 
Materials and 
methods 
recombinant 
DNA reagent  
pebioGFP-
Kif15_MDC 
(plasmid) 
This study N/A 
Described in 
Materials and 
methods 
recombinant 
DNA reagent  
pGW1-HA-
KBP 
(plasmid) 
This study N/A 
Described in 
Materials and 
methods 
recombinant 
DNA reagent  
pGW1-HA-
KBP_L1 
(plasmid) 
This study N/A 
Described in 
Materials and 
methods 
recombinant 
DNA reagent  
pGW1-HA-
KBP_L3 
(plasmid) 
This study N/A 
Described in 
Materials and 
methods 
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recombinant 
DNA reagent  
pGW1-HA-
KBP_L5 
(plasmid) 
This study N/A 
Described in 
Materials and 
methods 
recombinant 
DNA reagent  
pGW1-HA-
KBP_L10 
(plasmid) 
This study N/A 
Described in 
Materials and 
methods 
recombinant 
DNA reagent  
pGW1-HA-
KBP_L12 
(plasmid) 
This study N/A 
Described in 
Materials and 
methods 
recombinant 
DNA reagent  
pGW1-HA-
KBP_L14 
(plasmid) 
This study N/A 
Described in 
Materials and 
methods 
recombinant 
DNA reagent  
pGW1-HA-
KBP_L16 
(plasmid) 
This study N/A 
Described in 
Materials and 
methods 
recombinant 
DNA reagent  
pGW1-HA-
KBP_L18 
(plasmid) 
This study N/A 
Described in 
Materials and 
methods 
recombinant 
DNA reagent  
pGW1-HA-
KBP_L10+L1
2 (plasmid) 
This study N/A 
Described in 
Materials and 
methods 
recombinant 
DNA reagent  
pGW1-HA-
KBP_L10+L1
4 (plasmid) 
This study N/A 
Described in 
Materials and 
methods 
recombinant 
DNA reagent  
pGW1-HA-
KBP_L12+L1
4 (plasmid) 
This study N/A 
Described in 
Materials and 
methods 
recombinant 
DNA reagent  
pGW1-HA-
KBP_αHP4a 
(plasmid) 
This study N/A 
Described in 
Materials and 
methods 
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recombinant 
DNA reagent  
pGW1-HA-
KBP_αHP4b 
(plasmid) 
This study N/A 
Described in 
Materials and 
methods 
recombinant 
DNA reagent  
pGW1-HA-
KBP_αHP5a 
(plasmid) 
This study N/A 
Described in 
Materials and 
methods 
sequence-
based reagent 
KBP_fwd This study  
PCR primer 
for KBP 
mutants  
TATTATTA
TGGCGCGC
CAGGATCC
CCGGAATT
CGGCACGA
GGGAGGC
CGCTATGG
CGAACGTT
CCGTGGGC
A 
sequence-
based reagent 
KBP_rev This study  
PCR primer 
for KBP 
mutants  
CTCGTCGA
CTCCTAAT
CCTTAAGT
CAGGGCCA
TCTT 
sequence-
based reagent 
KBP_L1_fwd This study  
PCR primer 
for KBP_L1  
CTGCATAA
AAATCCGG
CAGCAGCA
CCAGCAGC
ATCCAAAT
ACAGCGCC 
sequence-
based reagent 
KBP_L1_rev This study  
PCR primer 
for KBP_L1 
GGCGCTGT
ATTTGGAT
GCTGCTGG
TGCTGCTG
CCGGATTT
TTATGCAG 
sequence-
based reagent 
KBP_L3_fwd This study  
PCR primer 
for KBP_L3  
TGAACCAC
ATCGACGC
AGGAGGA
CTGTCGGC
GGGGGA 
sequence-
based reagent 
KBP_L3_rev This study  
PCR primer 
for KBP_L3 
TCCCCCGC
CGACAGTC
CTCCTGCG
TCGATGTG
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GTTCA 
sequence-
based reagent 
KBP_L5_fwd This study  
PCR primer 
for KBP_L5 
ATCTTGTG
GTCTGAAG
CAGGAGC
AATTGAAA
CTGCACAG 
sequence-
based reagent 
KBP_L5_rev This study  
PCR primer 
for KBP_L5 
CTGTGCAG
TTTCAATT
GCTCCTGC
TTCAGACC
ACAAGAT 
sequence-
based reagent 
KBP_L10_fw
d 
This study  
PCR primer 
for 
KBP_L10  
TTTGGTCA
AACTGGAG
CAGGAGC
AGGAGCA
GGAGCAG
GACCAGCA
GGAGCAG
GAGCAGG
ACCAGGA
GGATATCA
TCAAAGAA
A 
sequence-
based reagent 
KBP_L10_re
v 
This study  
PCR primer 
for KBP_L10 
TTTCTTTG
ATGATATC
CTCCTGGT
CCTGCTCC
TGCTCCTG
CTGGTCCT
GCTCCTGC
TCCTGCTC
CTGCTCCA
GTTTGACC
AAA 
sequence-
based reagent 
KBP_L12_fw
d 
This study  
PCR primer 
for 
KBP_L12  
GAGTTCTT
TCAGATTG
GCGGCGCG
GTCACTGA
CCATATT 
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sequence-
based reagent 
KBP_L12_re
v 
This study  
PCR primer 
for KBP_L12 
AATATGGT
CAGTGACC
GCGCCGCC
AATCTGAA
AGAACTC 
sequence-
based reagent 
KBP_L14_fw
d 
This study  
PCR primer 
for KBP_L14 
TAGAGCCC
CTAACTGT
AGCAGCA
GGACCAGC
AGCATATC
TGTTGGTC
AAC 
sequence-
based reagent 
KBP_L14_re
v 
This study  
PCR primer 
for KBP_L14 
GTTGACCA
ACAGATAT
GCTGCTGG
TCCTGCTG
CTACAGTT
AGGGGCTC
TA 
sequence-
based reagent 
KBP_L16_fw
d 
This study  
PCR primer 
for 
KBP_L16  
TCCCTGAG
AGACCCAG
CAGCAGG
AGCACCAG
CAGGAGC
AGGAGCA
GGAGCAG
CACGCCCT
GCCATGTT
A 
sequence-
based reagent 
KBP_L16_re
v 
This study  
PCR primer 
for KBP_L16 
TAACATGG
CAGGGCGT
GCTGCTCC
TGCTCCTG
CTCCTGCT
GGTGCTCC
TGCTGCTG
GGTCTCTC
AGGGA 
sequence-
based reagent 
KBP_L18_fw
d 
This study  
PCR primer 
for 
KBP_L18  
ATTGTTGA
TTACTGTG
CAGCAGG
ACCAGGA
GCCGCCCA
GGAAATA 
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sequence-
based reagent 
KBP_L18_re
v 
This study  
PCR primer 
for KBP_L18 
TATTTCCT
GGGCGGCT
CCTGGTCC
TGCTGCAC
AGTAATCA
ACAAT 
sequence-
based reagent 
KBP_HP4a_f
wd 
This study  
PCR primer 
for KBP_L 
HP4a  
ACTCATAA
CCTATATG
CACTAGCT
GCAGTCTA
CCAGCATC
TG 
sequence-
based reagent 
KBP_L HP4a 
_rev 
This study  
PCR primer 
for KBP_ 
HP4a 
CAGATGCT
GGTAGACT
GCAGCTAG
TGCATATA
GGTTATGA
GT 
sequence-
based reagent 
KBP_HP4b_f
wd 
This study  
PCR primer 
for KBP_L 
HP4b  
AGTACACT
AAAACGC
GCACTTGA
GCACAATG
CC 
sequence-
based reagent 
KBP_L HP4b 
_rev 
This study  
PCR primer 
for KBP_ 
HP4b 
GGCATTGTG
CTCAAGTGC
GCGTTTTAGT
GTACT 
sequence-
based reagent 
KBP_HP5a_f
wd 
This study  
PCR primer 
for KBP_L 
HP5a  
GCTATCAA
TGCTGCTG
CGTTGTCA
GCGTTTTA
CATCAATA
AG 
sequence-
based reagent 
KBP_ HP5a 
_rev 
This study  
PCR primer 
for KBP_ 
HP5a 
CTTATTGA
TGTAAAAC
GCTGACAA
CGCAGCAG
CATTGATA
GC 
sequence-
based reagent 
KIF15_FRB_
fwd 
This study  
PCR primer 
for KIF15-
FRB 
AAGCTTGC
CACCATGG
GCGCGCCT
GCCACCAT
GGCTCCTG
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GCTGCAAA
TCT 
sequence-
based reagent 
KIF15_FRB_
rev 
This study  
PCR primer 
for KIF15-
FRB 
AGAGGATT
CTAGAAGC
AGGCGCGC
CAGCGTAG
TCTGGGAC
GTCGTATG
GGTAGAAT
TCTCCTGG
TGTCAGCT
GCCCAGA 
sequence-
based reagent 
bioGFPKIF1
5 _fwd 
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